Cardiovascular Disease in HIV Patients: A Comprehensive Overview

For decades, human immunodeficiency virus (HIV) was considered primarily an immunological threat. However, with advancements in antiretroviral therapy (ART) extending the lifespan of individuals living with HIV, cardiovascular disease (CVD) has emerged as a significant and growing concern. This article provides a comprehensive overview of the relationship between HIV and CVD, exploring the underlying mechanisms, clinical manifestations, diagnostic approaches, and treatment strategies.

The Rising Prevalence of CVD in HIV

The prevalence of cardiac involvement in individuals with HIV ranges considerably, reported between 28% and 73%.¹ This increase is directly linked to the improved survival rates achieved through effective HIV management. As people with HIV live longer, they are increasingly susceptible to the long-term complications of the virus and its treatment, including CVD.³

Pathogenesis of HIV-Associated Cardiovascular Disease

The development of CVD in HIV-infected individuals is multifactorial, involving both direct and indirect effects of the virus. Advances in cardiac imaging and immunology have deepened our understanding of the underlying processes.² Key mechanisms include:

• Chronic Inflammation: HIV infection induces a state of chronic immune activation and inflammation, even in individuals on ART. This inflammation contributes to endothelial dysfunction, atherosclerosis, and other cardiovascular complications.
• Direct Viral Effects: HIV can directly infect cardiac cells, leading to myocardial dysfunction and cardiomyopathy.
• ART-Related Factors: Some antiretroviral medications, particularly older protease inhibitors, have been associated with dyslipidemia (abnormal lipid levels) and insulin resistance, increasing the risk of CVD.
• Traditional Risk Factors: Individuals with HIV often have a higher prevalence of traditional CVD risk factors, such as hypertension, smoking, and diabetes.

Clinical Manifestations of CVD in HIV

HIV-associated CVD can manifest in various forms, including:

• Coronary Artery Disease (CAD): Increased risk of myocardial infarction (heart attack) and angina.
• Heart Failure: Weakening of the heart muscle, leading to reduced pumping efficiency.
• Cardiomyopathy: Disease of the heart muscle, often resulting in heart failure. Recent research highlights the specific link between HIV and cardiomyopathy, focusing on molecular mechanisms.⁴
• Arrhythmias: Irregular heartbeats.
• Pulmonary Hypertension: High blood pressure in the arteries of the lungs.
• Pericardial Disease: Inflammation of the sac surrounding the heart.

Diagnosis and Management

Diagnosing CVD in HIV-infected individuals requires a comprehensive approach, including:

• Clinical Evaluation: Thorough medical history and physical examination.
• Electrocardiogram (ECG): To assess heart rhythm.
• Echocardiography: Ultrasound of the heart to evaluate structure and function.
• Cardiac Magnetic Resonance Imaging (MRI): Provides detailed images of the heart.
• Biomarkers: Blood tests to measure cardiac enzymes and inflammatory markers.

Management strategies focus on:

• Optimizing ART: Selecting antiretroviral regimens with favorable cardiovascular profiles.
• Managing Traditional Risk Factors: Controlling blood pressure, cholesterol, and blood sugar.
• Lifestyle Modifications: Encouraging healthy diet, regular exercise, and smoking cessation.
• Pharmacological Therapy: Utilizing standard CVD medications, such as statins, beta-blockers, and ACE inhibitors, as appropriate.

Future Directions

Ongoing research is crucial to further elucidate the complex interplay between HIV and CVD. Future studies will focus on identifying novel biomarkers, developing targeted therapies, and implementing effective prevention strategies to reduce the burden of CVD in this vulnerable population. The long-term impact of HIV on cardiovascular health continues to evolve, necessitating continued vigilance and innovation in clinical care.